ArticleArchives of Razi Institute2024
Estimation of Salivary Levels of an Inhibitory Apoptotic Protein Survivin in Oral Leukoplakia and Squamous Cell Carcinoma.
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The process of carcinogenesis is initiated by an excessive proliferation of tumor cells, accompanied by a reduction in the rate of apoptosis. A number of molecules are involved in this process, with Survivin being one such molecule that is known to control it. The expression of Survivin has been observed in a range of embryonic and adult tissues with a high rate of turnover, as well as in tissue sections of oral precancerous and cancerous lesions. However, data regarding the detection of Survivin in saliva are scarce. The aim of this study is to estimate and compare salivary Survivin levels (SSL) in normal oral mucosa (NOM), oral leukoplakia (OL), and squamous cell carcinoma (OSCC) in order to demonstrate its potential as a predictive biomarker. Whole saliva samples were collected from all subjects and assessed for salivary Survivin levels using the ELISA technique. A Kruskal-Wallis test was employed to ascertain any significant differences in SSL. The mean SSL in the control group was found to be 301.9±180.35 ng/dl, while the study groups of OL and OSCC exhibited mean values of 285±140.4 and 316.5±176.72 ng/dl, respectively. In the OL group, the highest value was observed in cases of severe dysplasia (407.4 ng/dl), while in the OSCC group, the highest value was noted in WDSCC (311.5 ng/dl). Due to the inconsistency in the distribution of the sample, our findings were found to be non-significant (p = 0.796). This study is the first to detect Survivin in normal oral mucosa (NOM). The results suggest that Survivin plays a definitive role in maintaining the normal homeostasis of oral mucosa. The gradual upregulation and downregulation of SSL in OL and OSCC can be used to predict the aggressive nature of the malignancy. Therefore, the detection of Survivin in saliva can be utilized as a predictive marker for the progression of oral precancerous and cancerous lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.